GlassScriptPhysician profile
Helen P Carter
NPI 1629465281
$3,441.12
in general payments reported to CMS, 2019-2025
38 companies · $902 in 2025
The $902 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.15 · 2020: $167 · 2021: $205 · 2022: $466 · 2023: $981 · 2024: $654 · 2025: $902.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,536.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $790.17 | 2022-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $391.52 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $286.23 | 2021-2025 | |
| Lilly USA, LLC | $230.97 | 2020-2025 | Mounjaro, Zepbound, Emgality |
| Astrazeneca Pharmaceuticals LP | $229.64 | 2020-2025 | Farxiga, Breztri |
| Novartis Pharmaceuticals Corporation | $217.95 | 2023-2025 | |
| Exact Sciences Corporation | $159.76 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Amgen INC. | $139.03 | 2022-2025 | Otezla, Repatha, Prolia |
| Janssen Pharmaceuticals, INC | $96.16 | 2022-2024 | Spravato |
| Supernus Pharmaceuticals, INC. | $94.06 | 2021-2023 | Qelbree |
| Bayer Healthcare Pharmaceuticals INC. | $70.78 | 2022-2024 | |
| Axsome Therapeutics, INC. | $50.43 | 2025 | Symbravo, Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $49.90 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $49.47 | 2022 | |
| Ironshore Pharmaceuticals INC. | $47.36 | 2022-2023 | Jornay Pm |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $44.77 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $36.57 | 2024-2025 | Voquezna |
| Sanofi Pasteur INC. | $36.46 | 2019-2023 | |
| Corcept Therapeutics | $35.98 | 2025 | Korlym |
| Astellas Pharma US INC | $33.99 | 2025 | Veozah |
| Merck Sharp & Dohme LLC | $30.16 | 2024-2025 | Capvaxive, Vaxelis, Gardasil 9 |
| Insulet Corporation | $29.67 | 2024-2025 | Omnipod |
| Glaxosmithkline, LLC. | $29.64 | 2024-2025 | Trelegy Ellipta, Shingrix |
| Otsuka America Pharmaceutical, INC. | $26.82 | 2024 | Rexulti |
| Dexcom, INC. | $25.15 | 2021-2023 | Dexcom G6 Transmitter |
| Ironwood Pharmaceuticals, INC | $23.66 | 2024 | |
| Siemens Medical Solutions USA, INC. | $23.20 | 2024 | Dca Systems Hemoglobin A1c Reagent Kit |
| Abbott Laboratories | $20.86 | 2023 | Freestyle Libre 3 |
| Philips North America LLC | $19.54 | 2024 | (Ck7) Extended Holter |
| Medtronic Vascular, INC. | $18.96 | 2020 | |
| Angiodynamics, INC. | $15.06 | 2023 | Solero |
| Cranial Technologies, INC | $13.71 | 2020 | |
| Idorsia Pharmaceuticals US INC | $13.64 | 2023 | Quviviq |
| Alfasigma USA, INC. | $13.53 | 2021 | |
| Mannkind Corporation | $11.95 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.81 | 2021 | |
| Vbi Vaccine (Delaware) INC. | $11.46 | 2022 | |
| Genentech USA, INC. | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helen Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.